Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Immunology
IF: 1.404 5-Year IF: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Print: 1040-8401
ISSN Online: 2162-6472

Volumes:
Volume 40, 2020 Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v27.i5.30
pages 437-448

Gene Expression Signatures of Interleukin-2 In Vivo and In Vitro and Their Relation to Anticancer Therapy

Ping Jin
Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
Ena Wang
Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD
Maurizio Provenzano
Immune Oncology Section, Department of Surgery, University Hospital ZLF, Hebelstrasse 20, 4031 Basel, CH
David Stroncek
Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
Francesco M. Marincola
Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD

ABSTRACT

Treatment with human recombinant interleukin−2 (rIL−2) can successfully eradicate advanced cancer in humans; however, its utilization is limited by the unpredictability of its effectiveness and the excessive toxicity often associated with its use. The mechanisms responsible for immune-mediated tumor regression and those associated with limiting toxicity have not yet been sorted out. Thus, this review critically addresses what has been done in the past to understand this biologically and practically important question and discusses future strategies to enhance the understanding of this interesting model of immune-mediated tumor rejection. In particular, the first aim of this review is to discuss what is known about the mechanism(s) responsible for tumor rejection; the second aim is to review the relationship between the toxicity induced by rIL−2 treatment and its effectiveness; the third aim is to summarize novel insights into the possible mechanism of rIL−2 activity in vivo using high-throughput strategies aimed at the global assessment in real-time of events associated with rIL−2 therapy in humans. This information will not only lead to a better utilization of this biological agent in clinical practice but it may also provide important information about how immune-mediated tissue rejection occurs.


Articles with similar content:

Histone Deacetylases and Cancer-Associated Angiogenesis: Current Understanding of the Biology and Clinical Perspectives
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 1-2
Vincent Castronovo, Andrei Turtoi, Paul Peixoto, Akeila Bellahcene
Nitric Oxide in Cerebral Ischemic Neurodegeneration and Excitotoxicity
Critical Reviews™ in Neurobiology, Vol.12, 1998, issue 3
Paul J. L. M. Strijbos
Abstract of "Ethical, Legal, and Social Issues in Neurotechnology Research: Confronting the Boundaries and Considering the Implications"
Journal of Long-Term Effects of Medical Implants, Vol.18, 2008, issue 1
Dennis K. McBride
The Amelogenin "Enamel Proteins" and Cells in the Periodontium
Critical Reviews™ in Eukaryotic Gene Expression, Vol.18, 2008, issue 4
Carolyn W. Gibson
Highlights of the Fifth International Workshop on Nitric Oxide and Cancer
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 5-6
Claudia Ferroni, Greta Varchi, Valentina Rapozzi